Search
Testosterone propionate
go.drugbank.com/drugs/DB01420ApprovedInvestigationalVet approvedWithdrawn[T83] Testosterone propionate was developed initially by Watson labs, and FDA approved on February 5, 1974. … Currently, this drug has been discontinued in humans, but the vet application is still available as an OTC.[L1160]
Tinzaparin
go.drugbank.com/drugs/DB06822ApprovedInvestigationalLMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. … It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally.
Products: INNOHEP (20,000 IU/ML), INNOHEP (10,000 IU/ML)Recombinant stabilized RSV B prefusion F antigen
go.drugbank.com/drugs/DB18714ApprovedInvestigational[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of
Plozasiran
go.drugbank.com/drugs/DB18997ApprovedInvestigational[L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603]
Guselkumab
go.drugbank.com/drugs/DB11834ApprovedInvestigationalIL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation [A20357].
Sevoflurane
go.drugbank.com/drugs/DB01236ApprovedInvestigationalVet approved[L42340] Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. … Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia.
Casimersen
go.drugbank.com/drugs/DB14984ApprovedInvestigationalCasimersen was granted accelerated FDA approval on February 25, 2021, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with casimersen; this approval is contingent … Although corticosteroids effectively slow disease progression in both DMD and BMD patients, they do not address the underlying molecular pathogenesis.
Clidinium
go.drugbank.com/drugs/DB00771ApprovedIt is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
Mixtures: Nu-chlorax Capsules USPSynonyms: Bromuro de clidinio, Bromure de ClidiniumPalmitic Acid
go.drugbank.com/drugs/DB03796ApprovedInvestigationalA common saturated fatty acid found in fats and waxes including olive oil, palm oil, and body lipids.
Mixtures: Jayjun Real Water Shining Cleansing Foa M, Jayjun Real Water Shining Vita Cleansing Foa MZenocutuzumab
go.drugbank.com/drugs/DB15559ApprovedInvestigational[L56179] This approval was expedited following receipt of an FDA Commissioner’s National Priority Voucher. … [L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma.